GlaxoSmithKline to offload entire holding in Hindustan Unilever
The pharma giant acquired the stake in December 2018 as part of a transaction with Unilever
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 19 of 38
GlaxoSmithKline receives US approval for late-stage ovarian cancer treatment
Until now, only 20% of women with ovarian cancer were eligible to be treated with a drug of the same kind
GSK profits surge on demand for coronavirus treatments and shingles drug
"Responding to the Covid-19 pandemic is at the heart of our purpose as a company," said chief executive Emma Walmsley
GlaxoSmithKline, Sanofi team up to develop coronavirus vaccine
The candidate would enter clinical trials in the second half of 2020 and be available by the end of 2021
GlaxoSmithKline injects US$250mln into US biotech Vir in coronavirus treatment collaboration
Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays
GlaxoSmithKline injects cash into drug pipeline as earnings come in short
Full-year results showed turnover up 10% to £33.8bn and adjusted earnings per share up 4% to 123.9p, following a disappointing fourth quarter
Archive
FTSE 100 makes further gains as global rally continues
Britain's blue chips closed up over 42 points at 7,482. The midcap FTSE 250 added around 94 at 21,534
Archive
Health on the agenda, although coronavirus is not something Glaxo's results are likely to address
Aside from Glaxo, first-half results will be eyed from housebuilders Barratt Developments and Redrow, with Vodafone to issue an update
FTSE 100 starts February by closing higher, boosted by sterling, as no-deal fears resurface
FTSE 100 closed Monday ahead by around 40 points, or 0.55% at 7,326. Mid-cap cousin FTSE 250 gained over 63 at 21,207
GSK under the microscope in week ahead; BP and Royal Mail also eyed
Three housebuilders are also due to report on their numbers in the coming week: Barratt Developments, Bellway and Redrow
GlaxoSmithKline target price upped by UBS due to HIV drug
The ‘buy’ recommendation was maintained while the target price was lifted to 1,950p from 1,900p
GlaxoSmithKline receives HIV treatment knock-back in the USA
Glaxo's specialist HIV drugs division, in which Pfizer and Shionogi have stakes, has been developing the once-a-month injection as an alternative to daily treatments
UBS upgrades GSK as HIV business is set to grow rapidly
An injectable drug that launches in the US this year also might generate revenues of almost £700mln by 2023.
GlaxoSmithKline shares close to 17-year highs as it upgrades full-year earnings forecasts
The drugmaker now expects adjusted EPS for 2019 to be “around flat” year-on-year, an upgrade from a decline of between 3% and 5%
Archive
FTSE 100 closes higher ahead of US Fed decision; drugs titans shine
The UK's premier share index finished ahead by 24.52 points at 7,330, having been lower earlier
GSK sells two vaccines for up to €1bn
The company said it decided to sell these brands to focus on other segments within its fast-growing vaccines business
GSK recalls heartburn drug over carcinogen risk
The UK Medicines and Healthcare products Regulatory Agency (MHRA) said that all unexpired stock was going to be removed from pharmacies
GlaxoSmithKline to file blood cancer drug with regulators later this year
GSK bosses will use the results from this latest DREAMM-2 trial as the basis for the regulatory filings
GlaxoSmithKline develops HIV treatment that only needs to be taken six times a year
Glaxo already knew that its once-monthly jab worked, and it has now shown in clinical trials that the same injection but taken every two months is just as effective
Archive
Proactive news snapshot: hVIVO, Statpro, Keywords Studios...
A glance at some of the day's highlights from the Proactive Investors newswire